Tirzepatide dual incretin therapy for obesity
study033
10.1056/NEJMoa2206038
New England Journal of Medicine
randomized clinical trial
Tirzepatide evaluated as dual GIP/GLP-1 receptor agonist.
Significant body weight reductions observed in clinical trials.
tirzepatide
fat-loss|metabolism
advanced-metabolic-stack
semaglutide-vs-tirzepatide
published